Abstract:Objective A meta-analysis of randomised controlled trials on the efficacy and safety in patients with Gram-positive cocci infections treated with linezolid versus with vancomycin.Methods The data were collected from the MEDLINE,EMBASE,OVID,the Cochrane library,and CNKI.We also handsearched relevant journals.Randomized controlled trials comparing linezolid with vancomycin in patients with Gram-positive cocci infections were eligible for inclusion.Two investigators independently assessed the quality and extracted the data.The methodological quality of trails was assessed by the Jadad-scale plus allocation concealment.Heterogeneity was examined by chi-square test.Fixed effects model or random effects model were used to pool the data.Sensitivity analyses were used in the treatment course.Results Twelve randomized controlled studies comparing linezolid with vancomycin were analyzed,focusing on the 5,863 patients with Gram-positive cocci infections.It was found by meta-analysis that,with respect to clinical treatment success,linezolid was more effective than vancomycin in clinically evaluation patients at the end-of-treatment visit [OR 1.98,95%CI(1.32,2.98),P=0.001] and at the test-of-cure visit [OR 1.34,95%CI(1.01,1.76),P=0.04],and there was more effective than vancomycin in intention-to-treat patients at the test-of-cure visit [OR 1.20,95%CI(1.01,1.43),P=0.04].With respect to microbiological treatment success,linezolid was more effective than vancomycin in microbiologically evaluation patients at the test-of-cure visit [OR 1.39,95%CI(1.12,1.73),P=0.003].Additionally,empirical treatment with linezolid was associated with increased eradication rates for S.aureus strains [OR=1.84,95%CI(1.39,2.42),P<0.0001] and enterococcal species [OR=5.42,95%CI(1.49,19.71),P=0.01] in comparison with vancomycin in microbiologically evaluation patients at the test-of-cure visit.But,there was no difference in eradication rates for MRSA strains [OR=1.54,95%CI(0.97,2.45),P=0.07],Streptococcal species [OR=0.89,95%CI(0.31,2.54),P=0.82].Mortality was similar between the groups [OR=1.07,95%CI(0.89,1.28),P=0.50].Treatment with linezolid was not associated with more adverse effects in general in comparison with vancomycin [OR=1.10,95%CI(0.83,1.44),P=0.52].Conclusion Linezolid is more effective than vancomycin for treatment of patients with Gram-positive cocci infections although rigorously designed large sample size randomized double blind clinical trials are required to further demonstrate and support the conclusion.

Sensitivity analyses of linezolid against clinical gram-positive cocci isolates in vitro

Linezolid Resistance Mechanisms and Molecular Epidemiology of Clinical Isolates of Methicillin-Resistant Coagulase-Negative Staphylococci

Molecular Epidemiology and Antibiotic Resistance Profiles of Methicillin-Resistant Staphylococcus aureus Strains in a Tertiary Hospital in China.

Surveillance of antibiotic resistance in clinical isolates from First Affiliated Hospital of Zhejiang University Medical College in 2009

In Vitro Activities of Linezolid Against Clinical Isolates

Progress on the Resistance Mechanism of Enterococcus to Linezolid

Analysis of Genetic Diversity and Antibiotic Options for Clinical Listeria Monocytogenes Infections in China

The in vitro activity of linezolid against vancomycin-susceptible and-resistant Enterococcus faecium

Linezolid versus vancomycin for treatment of Gram-positive cocci infections:Meta-analysis of randomised controlled trials

Linezolid-Resistant Clinical Isolates of Meticillin-Resistant Coagulase-Negative Staphylococci and Enterococcus Faecium from China

In Vitro Antimicrobial Activity of Fosfomycin, Vancomycin and Daptomycin Alone, and in Combination, Against Linezolid-Resistant Enterococcus Faecalis

Comparative in vitro potency and kill curve activity of tedizolid and linezolid against Gram-positive bacteria isolated from Chinese hospitalized patients in 2013-2016.

Linezolid Resistance in Methicillin-Resistant Staphylococcus Epidermidis Strains Isolated in Hangzhou ;Area

In Vitro Activity of Contezolid Against Methicillin-Resistant Staphylococcus Aureus, Vancomycin-Resistant Enterococcus, and Strains with Linezolid Resistance Genes from China.

Multicentre evaluation of in vitro activity of contezolid against drug-resistant Staphylococcus and Enterococcus

Linezolid vs vancomycin for the treatment of Gram-positive cocci infections in intensive care uhit patients:meta-analysis for randomized controlled trials

Evaluation of the Antibacterial Effect in Vitro of Moxifloxacin and Linezolid on Nontuberculous Mycobacterium.

In Vitro Evaluation of the Antibacterial Activities of Radezolid and Linezolid for Streptococcus Agalactiae.

Study on the in vitro antibacterial activities of the antibacterial drugs against methicillin resistant coagulase-negative staphylococci

Effects and Safety of Linezolid vs.Vancomycin for the Treatment of Patients with MRSA: Meta Analysis of Randomized Controlled Trials

In Vitro Activities Of Tedizolid Compared With Other Antibiotics Against Gram-Positive Pathogens Associated With Hospital-Acquired Pneumonia, Skin And Soft Tissue Infection And Bloodstream Infection Collected From 26 Hospitals In China